Sovipostobart

• Description :

  Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic[1].

• CAS Number :

  [2649371-19-5]

• UNSPSC :

  12352203

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  CTLA-4

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/sovipostobart.html

• Purity :

  96.528

• Solubility :

  10 mM in DMSO

• Smiles :

  [Sovipostobart]

• Molecular Weight :

  (153.531 kDa)

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 36, No. 4, 2022.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported